Shire (LON:SHP)‘s stock had its “overweight” rating reaffirmed by equities researchers at Morgan Stanley in a research report issued to clients and investors on Friday. They currently have a GBX 5,700 ($76.34) target price on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 55.93% from the stock’s previous close.
Several other research analysts have also commented on the company. J P Morgan Chase & Co reissued an “overweight” rating and issued a GBX 5,300 ($70.98) price target on shares of Shire in a research report on Monday, October 30th. Liberum Capital reduced their price target on Shire from GBX 4,400 ($58.93) to GBX 4,200 ($56.25) and set a “hold” rating for the company in a report on Tuesday, October 24th. Deutsche Bank dropped their price objective on Shire from GBX 6,000 ($80.35) to GBX 5,700 ($76.34) and set a “buy” rating on the stock in a research report on Tuesday, September 5th. Barclays reissued an “equal weight” rating and issued a GBX 4,000 ($53.57) target price on shares of Shire in a research report on Monday, October 30th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a GBX 5,350 ($71.65) target price on shares of Shire in a research report on Tuesday, August 22nd. Four analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of GBX 5,277.78 ($70.68).
Shares of Shire (LON:SHP) opened at GBX 3,655.50 ($48.96) on Friday. Shire has a 1 year low of GBX 3,435.50 ($46.01) and a 1 year high of GBX 5,067 ($67.86).
TRADEMARK VIOLATION WARNING: “Shire (SHP) Receives Overweight Rating from Morgan Stanley” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/01/shire-shp-receives-overweight-rating-from-morgan-stanley.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.